Mucopolysaccharidosis type I (MPS I) is a rare inherited metabolic disorder caused by defects in alpha-L-iduronidase (IDUA), a lysosomal protein encoded by IDUA gene. MPS I is a progressive multisystemic disorder with a wide range of symptoms, including skeletal abnormalities and cognitive impairment, and is characterized by a wide spectrum of severity levels caused by varied mutations in IDUA. A human iPSC line was established from an attenuated MPS I (Scheie syndrome) patient carrying an IDUA gene mutation (c.266G > A; p.R89Q). This disease-specific iPSC line will be useful for the research of MPS I.
Resource 
Resource utility
MPS I is an autosomal recessive disorder caused by mutations of the IDUA gene. The disease pathophysiology is not well understood. iPSCs were generated from an MPS I patient with an IDUA gene mutation (c.266G > A; p.R89Q). These disease-specific iPSCs will be used to study the pathological mechanisms of MPS I.
Resource details
Mucopolysaccharidosis Type I (MPS I) is a lysosomal storage disorder caused by mutations of the alpha-L-iduronidase (IDUA) gene (Poletto et al., 2018; Yamagishi et al., 1996) . The condition affects many parts of the body, including the brain, musculoskeletal system, heart, lungs, and eyes. Mutations of the IDUA gene lead to IDUA enzyme deficiency, resulting in the accumulation of glycosaminoglycans (GAGs), heparan sulfate and dermatan sulfate in cells and especially in lysosomes. This causes many organs and tissues of the body to become enlarged in MPS I. More than one hundred different mutations of the IDUA gene have been identified in individuals with MPS I. These variations result in a broad range of severity levels and disease progression patterns among individuals with MPS I (Poletto et al., 2018; Yamagishi et al., 1996) . However, the disease pathophysiology is largely unknown. MPS I-specific iPSCs can be used to understand the pathophysiological mechanism of MPS I. We established and characterized an iPSC line from a patient with attenuated MPS I who carried an IDUA gene mutation (c.266G > A; p.R89Q). MPS I-specific iPSCs were generated from peripheral blood mononuclear cells (PBMCs) of an MPS I patient using episomal vectors carrying reprogramming factors under feederfree culture conditions (Nakagawa et al., 2014; Okita et al., 2013) . The MPS I-specific iPSC (HPS0660) presented a human ES cell-like morphology. The iPSCs were found to be positive for pluripotent marker NANOG and SSEA4 by immunocytochemistry ( Fig. 1A , green: NANOG, red: SSEA4), and 99.9% of the iPSCs were found to be positive for pluripotent marker SSEA4 by flow cytometry. The three-germ-layer differentiation capacities of the iPSCs were revealed with an in vitro EB Fig. 1 . Characterization of the iPSC line.
M. Suga, et al. Stem Cell Research 36 (2019) 101406 formation assay (Fig. 1C , Tubulin βIII: ectoderm, D, SOX17: endoderm, and E, smooth muscle actin (SMA): mesoderm). Furthermore, the iPSCs retained the IDUA gene mutation and normal karyotype. The identity of the cell line was verified with an STR analysis. Mycoplasma contamination was not detected in the cell culture.
Materials and methods

Ethics statement
The generation and use of human iPSCs was approved of by Ethics Committees of RIKEN BioResource Research Center, Department of Medicine and Graduate School of Medicine of Kyoto University. All methods used in this study were performed in accordance with approved guidelines. Formal informed consent was obtained from the patient.
Establishment of iPSCs
The iPSCs were generated from peripheral blood mononuclear cells (PBMCs) obtained from a patient with attenuated MPS I, according to the protocol for the generation and culture of human iPSCs under feeder-free conditions (Nakagawa et al., 2014, http://www.cira.kyotou.ac.jp/e/research/protocol.html) . In brief, the PBMCs were cultured for 5 days in MNC medium; StemSpan-ACF medium (STEMCELL Technologies, Vancouver, Canada), supplemented with 100 ng/ml rhSCF, 100 ng/ml rhTPO, 100 ng/ml rhFlt3L, 50 ng/ml rhIL-6, 20 ng/ ml rhIL-3 (all from R&D Systems, Minneapolis, MN). The episomal vectors (pCE-hOCT3/4 [0.63 μg], pCE-hSK [SOX2 and KLF4, 0.63 μg], pCE-hUL [L-MYC and LIN28, 0.63 μg], pCE-mp53DD [p53 carboxyterminal dominant-negative fragment, 0.63 μg], and pCXB-EBNA1 [0.5 μg]) were transduced into PBMCs (3,000,000 cells) by electroporation using the Nucleofector 2b Device with a Human CD34+ Cell Nucleofector Kit (Lonza, Basel, Switzerland). The electroporated cells were plated in MNC medium on iMatrix-511 E8 fragment (MATRIX-OME, Osaka, Japan)-coated cell culture plates and cultured in a CO 2 incubator at 37°C under 5% CO 2 . For two to eight days after the electroporation, an equal volume of StemFit medium was added to the culture wells every other day without aspiration, then the culture medium was replaced with StemFit medium to induce iPSCs. The cells were cultured in the CO 2 incubator at 37°C under 5% CO 2 for 14-18 days until iPSC colonies were observed. The selected iPSC clone was expanded and maintained using StemFit medium and iMatrix-511 E8 fragment (Nakagawa et al., 2014) . The iPSCs were single-cell passaged every 6-8 days using 0.5× TrypLE Select (TrypLE Select (Gibco, Thermo Fisher, Waltham, MA) diluted 1:1 with 0.5 mM EDTA solution). The plating density was 1350 cells per cm 2 . 10 μM Y-27632 (Wako, Osaka, Japan) was added to StemFit medium when the iPSCs were passaged, and was removed by replacing the medium with fresh StemFit medium the next day.
Karyotyping
A G-band analysis was performed by LSI Medience (Tokyo, Japan) to determine the karyotype of the iPSC line at passage number 6. A total of 20 metaphases were analyzed.
Genotyping
Genomic DNA of undifferentiated state iPSCs at passage number 4 and the parental PBMCs was extracted using a PureLink Genomic DNA Mini Kit (Invitrogen, Thermo Fisher Scientific) and amplified by a PCR using the enzyme KOD Plus Neo (TOYOBO, Japan) and Veriti thermal cycler (Applied Biosystems, Thermo Fisher Scientific). The thermocycling conditions were as follows: initial denaturation at 94°C for 2 min, 35 cycles of 2-step thermocycling (denaturation at 98°C for 10 s and extension at 68°C for 30 s), and hold at 10°C. The targeted PCR product was extracted from agarose gel using a PureLink Quick Gel Extraction Kit (Invitrogen, Thermo Fisher Scientific) and then subjected to direct sequencing using a BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Thermo Fisher Scientific) according to manufacturers' instructions. A 3500xL Genetic Analyzer (Applied Biosystems, Thermo Fisher Scientific) was used for the sequencing analyses. The primer set used for genotyping is listed in Table 2 .
In vitro three-germ-layer differentiation assay
An embryoid body (EB) formation assay was performed to differentiate iPSCs into three germ layers. EBs were formed from the 0.5× TrypLE Select-dissociated iPSCs (9000 cells per EB) in DMEM/F12 medium supplemented with 20% KSR, 2 mM L-glutamine, 0.1 mM NEAA, 0.1 mM 2-mercaptoethanol (All from Gibco, Thermo Fisher Scientific), 10 μM Y-27632 (Nacalai Tesque, Kyoto, Japan) using a lowattachment surface V-bottom 96-well plate (Sumitomo Bakelite, Tokyo, Japan) for 11 days, and then cultured in DMEM containing 10% FBS (Gibco, Thermo Fisher Scientific) on a Matrigel (BD Bioscience)-coated tissue culture plate for 7 days Table 1 .
Immunocytochemistry
Indirect fluorescent immunostaining was performed. Cells were fixed in 4% paraformaldehyde (Nacalai Tesque) in PBS for 20 min at room temperature. For permeabilization and blocking, the fixed cells Suga, et al. Stem Cell Research 36 (2019) 101406 were incubated with blocking buffer: PBS containing 5% Blocking One (Nacalai Tesque) and 0.2% Triton-X 100 (Nacalai Tesque). The primary and secondary antibodies used in this study are listed in Table 2 . Primary antibodies and secondary antibodies were reacted in the blocking buffer for 16 h (overnight) at 4°C and for 1 h at room temperature, respectively. Nuclei were stained with DAPI (Invitrogen, Thermo Fisher Scientific). Images were obtained with a BZ-X710 microscope (Keyence, Osaka, Japan).
Flow cytometry
The iPSCs were dissociated with Accumax solution (Sigma Aldrich, St. Louis, MO). The dissociated iPSCs were suspended in PBS containing 2% FBS (Stain buffer, BD Bioscience, San Jose, CA) at a density of 1.0 × 10 6 cells/ml. The cells were stained for 30 min on ice and analyzed with FACS Aria (BD Bioscience). The Alexa Fluor 647-labeled antibodies used for flow cytometry are listed in Table 2 . The FlowJo software program (ver.10, FLOWJO, BD Bioscience) was used for the data analysis.
STR analysis
Genomic DNA was extracted from the iPSCs and PBMCs using a PureLink Genomic DNA Mini Kit and subjected to an STR analysis using PowerPlex® 16 System (Promega, Madison, WI).
Mycoplasma test
iPSCs were confirmed to be mycoplasma-negative by indirect DNA fluorescent staining and a nested-PCR. iPSC culture medium was tested by staining with Hoechst33258 (Thermo Fisher Scientific) after 5-6 days of co-culture with VERO cells (RCB0001, RIKEN BRC Cell Bank) as mycoplasma negative indicator cells. DNA was extracted and subjected to a nested-PCR. The primers used in the PCR are listed in Table 2 . AmpliTaq Gold 360 DNA Polymerase (Thermo Fisher Scientific) was used for each step of the PCR. The same thermocycling conditions were used for both steps: initial denaturation of 10 min at 95°C, 30 cycles of thermocycling; 30 s at 95°C; 2 min at 55°C; 2 min at 72°C, final extension of 5 min at 72°C, and hold at 10°C. The PCR products were detected by electrophoresis on 2% agarose gel and ethidium bromide staining.
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